Rainer F Storb

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
    Rainer Storb
    University of Washington, USA
    J Clin Oncol 31:1530-8. 2013
  2. pmc Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects
    Rainer Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA
    Biol Blood Marrow Transplant 19:792-8. 2013
  3. pmc Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation
    Maura H Parker
    Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Mailstop D1 100, Seattle, WA, 98109 1024, USA
    Skelet Muscle 2:4. 2012
  4. pmc Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
    Rainer Storb
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:S18-27. 2010
  5. pmc Reduced-intensity conditioning transplantation in myeloid malignancies
    Rainer Storb
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Curr Opin Oncol 21:S3-5. 2009
  6. ncbi request reprint Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 872:372-5; discussion 375-6. 1999
  7. ncbi request reprint Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle 98109, USA
    Biol Blood Marrow Transplant 7:39-44. 2001
  8. ncbi request reprint Perspective: haematopoietic stem cell rescue enabling high-dose chemotherapy, tool for immunotherapy
    R Storb
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Dev Biol (Basel) 108:123-6. 2002
  9. ncbi request reprint Non-myeloablative allogeneic transplantation -- state-of-the-art
    Rainer Storb
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Pediatr Transplant 8:12-8. 2004
  10. ncbi request reprint History of pediatric stem cell transplantation
    Rainer Storb
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Pediatr Transplant 8:5-11. 2004

Research Grants

Detail Information

Publications101 found, 100 shown here

  1. pmc Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
    Rainer Storb
    University of Washington, USA
    J Clin Oncol 31:1530-8. 2013
    ..The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities...
  2. pmc Allogeneic hematopoietic cell transplantation following minimal intensity conditioning: predicting acute graft-versus-host disease and graft-versus-tumor effects
    Rainer Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA, USA
    Biol Blood Marrow Transplant 19:792-8. 2013
    ..These findings suggest that the immunologic mechanisms involved in acute GVHD might differ from those that initiate graft-versus-tumor effects...
  3. pmc Inhibition of CD26/DPP-IV enhances donor muscle cell engraftment and stimulates sustained donor cell proliferation
    Maura H Parker
    Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Mailstop D1 100, Seattle, WA, 98109 1024, USA
    Skelet Muscle 2:4. 2012
    ..abstract:..
  4. pmc Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease?
    Rainer Storb
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:S18-27. 2010
    ..This review is meant to highlight the advantages and disadvantages of the "standard of care" and assess the prospects for future regimens that may be more effective...
  5. pmc Reduced-intensity conditioning transplantation in myeloid malignancies
    Rainer Storb
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington, USA
    Curr Opin Oncol 21:S3-5. 2009
    ..Reduction of the tumor burden before HCT with targeted therapy such as radiolabelled anti-CD45 antibody may improve the outcome. Despite still existing problems, early results in elderly patients with AML/MDS have been encouraging...
  6. ncbi request reprint Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 872:372-5; discussion 375-6. 1999
    ..This paper describes the development of nonmyeloablative marrow transplant programs that have little toxicity in a canine model and their translation to patients with malignant and nonmalignant hematological diseases...
  7. ncbi request reprint Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle 98109, USA
    Biol Blood Marrow Transplant 7:39-44. 2001
    ..We conclude that the cyclophosphamide/antithymocyte globulin regimen combined with methotrexate/cyclosporine after transplantation is well tolerated and effective in heavily pretreated patients with aplastic anemia...
  8. ncbi request reprint Perspective: haematopoietic stem cell rescue enabling high-dose chemotherapy, tool for immunotherapy
    R Storb
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Dev Biol (Basel) 108:123-6. 2002
  9. ncbi request reprint Non-myeloablative allogeneic transplantation -- state-of-the-art
    Rainer Storb
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Pediatr Transplant 8:12-8. 2004
    ..For non-malignant diseases, the procedure can be used to establish a stable state of mixed donor/host hematopoietic chimerism, which, in itself, may be sufficient to cure disease manifestations...
  10. ncbi request reprint History of pediatric stem cell transplantation
    Rainer Storb
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109 1024, USA
    Pediatr Transplant 8:5-11. 2004
    ....
  11. ncbi request reprint Current and future preparative regimens for bone marrow transplantation in thalassemia
    R Storb
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Ann N Y Acad Sci 850:276-87. 1998
    ..Mixed donor/host chimerism (> or = 50% donor cells in all lineages) has persisted for > 80 weeks, even though immunosuppression was discontinued after five weeks...
  12. ncbi request reprint Allogeneic hematopoietic stem cell transplantation--yesterday, today, and tomorrow
    Rainer Storb
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA 98109, USA
    Exp Hematol 31:1-10. 2003
    ....
  13. ncbi request reprint Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant
    Lyle C Feinstein
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 9:266-72. 2003
    ..4; P =.04). Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting...
  14. pmc Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation
    Marcello Rotta
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 115:1288-95. 2010
    ..009). These results suggest that donor statin treatment may be a promising strategy to prevent severe acute GVHD without compromising immunologic control of the underlying malignancy...
  15. pmc A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1088-92. 2011
    ..A larger registry study should be performed to provide more definitive information comparing outcomes with the 2 calcineurin inhibitors...
  16. ncbi request reprint Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model
    J M Zaucha
    Clinical Research Division, Fred Hutchinson Cancer Research Center Washington, Seattle 98109-1024, USA
    Biol Blood Marrow Transplant 7:513-6. 2001
    ..11). However, increasing the duration of posttransplantation immunosuppression with CSP from 35 to 100 days favorably influenced stable donor engraftment (P = .06)...
  17. ncbi request reprint Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation
    V Ratanatharathorn
    University of Michigan, Ann Arbor Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 92:2303-14. 1998
    ..The survival disadvantage in advanced disease patients receiving tacrolimus warrants further investigation...
  18. pmc Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts
    Boglarka Gyurkocza
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 15:1314-22. 2009
    ..We concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using conditioning with Flu and low-dose TBI...
  19. pmc Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 118:456-63. 2011
    ..In patients without GVHD, early withdrawal of IST might help to prevent relapse during the first 18 months, but other interventions would be needed to prevent relapse at later time points...
  20. pmc Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 114:5444-53. 2009
    ..This study was registered at www.clinicaltrials.gov as #NCT00008177...
  21. ncbi request reprint CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transpla
    J M Zaucha
    Fred Hutchinson Cancer Research Center, The University of Washington, and the Veterans Affairs Medical Center, Seattle, WA 98109-1024, USA
    Blood 98:3221-7. 2001
    ..Given the morbidity associated with extensive chronic GVHD, efforts to further accelerate engraftment in HLA-matched sibling transplants by increasing CD34 cell number in G-PBMC products may be counterproductive...
  22. pmc Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting
    Marcello Rotta
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:3383-91. 2009
    ..03 and P = .02) and PFS (P = .04 and P = .03), whereas Karnofsky scores less than 90% at allotransplantation correlated with shorter PFS only (P = .005). Long-term disease control and GVHD remain key issues...
  23. pmc A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1308-15. 2011
    ..In conclusion, the maximal tolerated induction dose of IL-2 combined with DLI appears to be 1.0 × 10(6) IU/m(2)/day. IL-2 administration after DLI might increase the incidence of cGVHD...
  24. ncbi request reprint Non-myeloablative hematopoietic stem cell transplantation
    M Maris
    Fred Hutchinson Cancer Research Center, Seattle, WA, United States
    Transfus Clin Biol 8:231-4. 2001
    ....
  25. ncbi request reprint High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation
    F Baron
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Leukemia 19:822-8. 2005
    ..These data suggest more rapid engraftment of donor T cells and reduced rejection rates could be achieved by increasing the doses of CD34(+) cells in unrelated grafts administered after nonmyeloablative conditioning...
  26. pmc Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 118:1421-8. 2011
    ..These data indicate that the majority of long-term survivors after transplantation for AA during childhood can have a normal productive life...
  27. pmc Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
    Andrew R Rezvani
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA 98109, USA
    Br J Haematol 143:395-403. 2008
    ..Non-myeloablative allogeneic HCT can produce long-term disease-free survival in patients with chemosensitive relapsed DLBCL who have failed or are ineligible for autologous HCT...
  28. ncbi request reprint G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required
    J M Zaucha
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109-1024, USA
    Biol Blood Marrow Transplant 7:613-9. 2001
    ....
  29. pmc Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA and
    Blood 117:3214-9. 2011
    ..These results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronic GVHD is not simply the end stage of acute GVHD...
  30. pmc Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation
    Ron Ram
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1537-45. 2011
    ..We conclude that despite relapse of lymphoma after RIC HCT, some patients may experience prolonged survival, with better postrelapse outcomes occurring in patients with indolent NHL, HL, or late relapse...
  31. ncbi request reprint Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders
    L M Burroughs
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 40:633-42. 2007
    ..However, there was a risk of GVHD, which is an undesirable outcome for this group of patients...
  32. ncbi request reprint Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings
    F Weissinger
    Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, USA
    Blood 98:3584-8. 2001
    ....
  33. ncbi request reprint Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning
    J P Panse
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 128:659-67. 2005
    ..01). These results suggest that the dosing of certain cellular subsets of PBSC products can influence important outcomes post-HCT after non-myeloablative conditioning...
  34. ncbi request reprint Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation
    Takahiro Fukuda
    Program in Pulmonary Critical Care Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98109, USA
    Blood 102:2777-85. 2003
    ..These findings support the concept that lung damage from the conditioning regimen plays a crucial role in the development of IPS after HSCT...
  35. pmc Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:1011-6. 2010
    ..Further effort is needed to reduce the burden of disease and treatment-related complications in this population...
  36. pmc Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation
    Andrew R Rezvani
    Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington Medical Center, 1100Fairview Ave N, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:1594-601. 2011
    ..We conclude that change in serum albumin concentration from baseline to initiation of aGVHD treatment is an inexpensive, readily available, and predictive biomarker of GVHD severity and mortality after reduced-intensity allogeneic HCT...
  37. pmc Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation
    Luisa Giaccone
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 106:4381-8. 2005
    ..We conclude that increased MPA Css's predicted higher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css's greater than 2.5 microg/mL could prevent graft rejection...
  38. pmc ⁹⁰Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma
    Ajay K Gopal
    Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA, USA
    Blood 118:1132-9. 2011
    ..The addition of ⁹⁰Y-ibritumomab tiuxetan to NMAT is safe and yields early responses and prolonged disease control in some of the highest-risk B-NHL patients. This trial was registered at www.clinicaltrials.gov as #NCT00119392...
  39. ncbi request reprint Invasive aspergillosis before allogeneic hematopoietic stem cell transplantation: 10-year experience at a single transplant center
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:494-503. 2004
    ....
  40. ncbi request reprint Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors
    M Goerner
    Divisions of Clinical Research and Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 98:2065-70. 2001
    ..In summary, these results show that RD114-pseudotype oncoretroviral vectors are able to transduce hematopoietic long-term repopulating cells and, thus, may be useful for human stem cell gene therapy...
  41. ncbi request reprint Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 102:827-33. 2003
    ..More effective strategies are needed to prevent invasive mold infections, which currently account for a notable proportion of nonrelapse mortality after nonmyeloablative allogeneic HCT...
  42. ncbi request reprint Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML
    F R Kerbauy
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Leukemia 19:990-7. 2005
    ..The 2-year survival estimates for patients in CP1 (n=14) and beyond CP1 (n=10) were 70 and 56%, respectively. This study shows encouraging remission rates for patients with CML not eligible for conventional allografting...
  43. ncbi request reprint Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis
    B L Scott
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Leukemia 20:128-35. 2006
    ..Randomized prospective studies are needed to further address the optimal choice of transplant conditioning intensity in myeloid neoplasms...
  44. ncbi request reprint Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation
    K Robien
    Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Bone Marrow Transplant 37:687-92. 2006
    ..Our results suggest that concurrent folic acid supplementation does not change MTX effectiveness or toxicity in this patient population...
  45. ncbi request reprint Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality
    Mohamed L Sorror
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA Division of Medical Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA
    Blood 124:287-95. 2014
    ..The HCT-CI could be useful in designing trials for GVHD prevention and could inform expectations for GVHD treatment trials. ..
  46. pmc Allogeneic hematopoietic cell transplantation: the state of the art
    Boglarka Gyurkocza
    Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, WA, USA
    Expert Rev Hematol 3:285-99. 2010
    ..We conclude with a speculative outline of the next 5 years of research in the field of HCT...
  47. ncbi request reprint IL-2 does not enhance the conversion to complete donor chimerism following nonmyeloablative hematopoietic cell transplantation in dogs
    G E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Bone Marrow Transplant 31:1027-31. 2003
    ..These results show that IL-2 given with DLI after nonmyeloablative transplantation in dogs is not effective in reliably converting mixed to complete donor chimerism...
  48. ncbi request reprint De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival
    J L Wagner
    Clinical Research, Department of Medicine, University of Washington, Seattle, USA
    Biol Blood Marrow Transplant 6:633-9. 2000
    ....
  49. ncbi request reprint Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial
    E Kansu
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Blood 98:3868-70. 2001
    ..76; 95% confidence interval, 0.48-1.21; P =.25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival...
  50. ncbi request reprint Purified canine CD34+Lin- marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesis
    B Bruno
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical School, Seattle, USA
    Biol Blood Marrow Transplant 7:543-51. 2001
    ..Whereas canine CD34+Lin- marrow cells contributed to long-term multilineage hematopoiesis, progeny of CD34-Lin- progenitor cells were not detected after transplantation in these experiments...
  51. ncbi request reprint Hematopoietic responses to stress conditions in young dogs compared with elderly dogs
    J M Zaucha
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109-1024, USA
    Blood 98:322-7. 2001
    ....
  52. ncbi request reprint Molecular cloning and in vivo evaluation of canine granulocyte-macrophage colony-stimulating factor
    R A Nash
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98104
    Blood 78:930-7. 1991
    ..Evaluation of survival times of 51Cr-labeled autologous platelets suggested increased consumption as the primary reason for thrombocytopenia. A species-specific GM-CSF will be a useful tool for hematologic or immunologic studies in dogs...
  53. pmc Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation
    Andrew R Rezvani
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center and University of Washington, 1100 Fairview Ave N, MS D1 100, Seattle, WA 98109, USA
    J Autoimmun 30:172-9. 2008
    ..Ultimately, advances in separation of GVT from GVHD will further enhance the potential of allogeneic HCT as a curative treatment for hematological malignancies...
  54. ncbi request reprint Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation
    Jason W Chien
    Clinical Research Division, Fred Hutchinson Cancer Research Center Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:288-96. 2005
    ....
  55. doi request reprint Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens
    O Sala-Torra
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98119, USA
    Bone Marrow Transplant 41:887-93. 2008
    ..Serious GVHD may be considered as an endpoint in clinical trials with GVHD-related outcomes...
  56. ncbi request reprint Mixed allogeneic chimerism and graft-versus-leukemia effects in acute myeloid leukemia
    R Storb
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 19024, USA
    Leukemia 16:753-4. 2002
  57. pmc Thyroid function following hematopoietic cell transplantation in children: 30 years' experience
    Jean E Sanders
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 113:306-8. 2009
    ..008). Thyroid tumors occurred at a median of 9.9 (4.5-22.3) years after HCT and included 13 with papillary carcinoma and 5 with benign adenomas. Children who receive a HCT should be monitored for thyroid abnormalities throughout life...
  58. ncbi request reprint Dog class I gene DLA-88 histocompatibility typing by PCR-SSCP and sequencing
    J L Wagner
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Tissue Antigens 55:564-7. 2000
    ..In this study, polymerase chain reaction single-stranded conformational polymorphism was used to separate alleles, thereby allowing sequenced-based typing...
  59. ncbi request reprint A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest
    H Al-Ghamdi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Br J Haematol 113:461-9. 2001
    ..Further studies will be needed to determine if similar methods could be used in randomized clinical trials for prevention of GVHD...
  60. ncbi request reprint Treatment of marrow graft recipients with thymopentin
    R P Witherspoon
    Department of Medicine, University of Washington, Seattle
    Bone Marrow Transplant 1:365-71. 1987
    ....
  61. ncbi request reprint Reducing transplant toxicity
    L Feinstein
    Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Curr Opin Hematol 8:342-8. 2001
    ..If long-term efficacy is demonstrated, such strategies will expand the options for patients who would not qualify for conventional allogeneic transplants...
  62. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation
    L Feinstein
    Program in Transplantation Biology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA
    Curr Opin Oncol 13:95-100. 2001
    ..Preliminary results are encouraging. If long-term efficacy is demonstrated, such strategies would expand treatment options for patients who would otherwise be excluded from receiving conventional allografts...
  63. ncbi request reprint Allogeneic bone marrow transplantation in children with myelodysplastic syndrome or juvenile myelomonocytic leukemia: the Seattle experience
    U Yusuf
    Fred Hutchinson Cancer Research Center and University of Washington Department of Pediatrics, Seattle, WA 98109, USA
    Bone Marrow Transplant 33:805-14. 2004
    ..5 times more likely to relapse (P=0.01). The median follow-up among the 43 surviving patients is 10 years (range 1-25). We conclude that allogeneic BMT for children with MDS is well tolerated and can be curative...
  64. ncbi request reprint Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission
    Lyle C Feinstein
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Br J Haematol 120:281-8. 2003
    ..While follow-up is short, this analysis demonstrates that the procedure is sufficiently safe to be studied in a wider group of patients...
  65. ncbi request reprint Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect
    L Feinstein
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D1 100, P O Box 19024, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 938:328-37; discussion 337-9. 2001
    ..Remissions occurred gradually over periods of weeks to a year. If long-term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting...
  66. ncbi request reprint Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
    Chien Shing Chen
    Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington, School of Medicine Seattle, WA, USA
    Bone Marrow Transplant 32:515-22. 2003
    ..5, P=0.007). Our data suggest that extension of PCP prophylaxis may be beneficial in high-risk autograft recipients. Further study of long-term anti-infective prophylaxis based on patient risk factors after SCT appear warranted...
  67. ncbi request reprint Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
    H J Deeg
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 95:1188-94. 2000
    ..These data indicate that BMT can be carried out successfully in patients with MDS who are older than 55 years of age. (Blood. 2000;95:1188-1194)..
  68. ncbi request reprint Myeloablation by intravenous busulfan and hematopoietic reconstitution with autologous marrow in a canine model
    H J Deeg
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 5:316-21. 1999
    ..However, factors other than absorption influence the AUC, and individualization of dosing may be required even with intravenous administration of the drug...
  69. ncbi request reprint A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
    P J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center Department of Medicine, Seattle, WA, USA
    Blood 94:2192-9. 1999
    ..The correlation between graft failure and the number of CD8 cells in the donor marrow supports the hypothesis that donor CD8 cells help to prevent marrow graft rejection...
  70. ncbi request reprint Mixed chimerism: preclinical studies and clinical applications
    P A McSweeney
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 5:192-203. 1999
    ..For patients with malignancy, infusion of additional donor lymphocytes may be needed to effectively treat underlying disease...
  71. ncbi request reprint Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus-pseudotype retroviral vector
    H P Kiem
    Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Gene Ther 6:966-72. 1999
    ..Furthermore, these results demonstrate that the monoclonal antibody to canine CD34 used in this study is able to enrich for hematopoietic repopulating cells...
  72. ncbi request reprint Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome
    D C Matthews
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Departments of Pediatrics, Medicine and Radiology, University of Washington, Seattle, WA, USA
    Blood 94:1237-47. 1999
    ..We conclude that (131)I-anti-CD45 antibody can safely deliver substantial supplemental doses of radiation to bone marrow (approximately 24 Gy) and spleen (approximately 50 Gy) when combined with conventional CY/TBI...
  73. ncbi request reprint DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing
    J L Wagner
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Tissue Antigens 52:397-401. 1998
    ....
  74. ncbi request reprint Molecular analysis and polymorphism of the DLA-DQB genes
    J L Wagner
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Tissue Antigens 52:242-50. 1998
    ..The number of nonsynonymous changes was higher than the number of synonymous changes in the putative antigen recognition sites suggestive of positive selection...
  75. ncbi request reprint Unrelated and HLA-nonidentical related donor marrow transplantation for thalassemia and leukemia. A combined report from the Seattle Marrow Transplant Team and the International Bone Marrow Transplant Registry
    K M Sullivan
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Ann N Y Acad Sci 850:312-24. 1998
    ..Using the paradigm of CML, it is likely that access to curative therapy of thalassemia will improve with optimal HLA typing and donor selection early in the course of disease...
  76. ncbi request reprint A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery
    K M Sullivan
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Biol Blood Marrow Transplant 2:44-53. 1996
    ..03). We conclude that in the absence of hypogammaglobulinemia, monthly administration of IVIg given from day 90 to 360 does not reduce late complications and may impair long-term humoral immune recovery after marrow transplantation...
  77. ncbi request reprint Nonmyeloablative hematopoietic cell transplant for treatment of immune deficiency
    A Woolfrey
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, Washington 98109, USA
    Curr Opin Pediatr 13:539-45. 2001
    ..Results of NM-HCT in a small number of patients indicate that this procedure may play an important role in treating life-threatening immune deficiencies...
  78. ncbi request reprint Allelic variation in the DR subregion of the canine major histocompatibility complex
    U M Sarmiento
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104
    Immunogenetics 32:13-9. 1990
    ..Cluster analysis of the nucleotide and predicted amino acid sequences subdivided the DLA-DRB alleles into three major allelic groups which may represent the canine counterparts of the supertypic groups described in man...
  79. ncbi request reprint Survival of small bowel transplants in canine mixed hematopoietic chimeras: preliminary results
    M Y Yunusov
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA
    Transplant Proc 34:3366-7. 2002
  80. ncbi request reprint Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors
    R A Nash
    Clinical Research Division, Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle, WA, USA
    Blood 96:2062-8. 2000
    ....
  81. pmc Immunomodulatory effects of mixed hematopoietic chimerism: immune tolerance in canine model of lung transplantation
    R A Nash
    Fred Hutchinson Cancer Research Center, bUniversity of Washington School of Medicine, Seattle, WA, USA
    Am J Transplant 9:1037-47. 2009
    ..Establishing MC is immunomodulatory and observed changes were consistent with activation of both the effector and regulatory immune response...
  82. ncbi request reprint Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism
    C M Ulrich
    Public Health Sciences Division and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Blood 98:231-4. 2001
    ..23; 34% slower to 20 000/microL, P =.08). Patients with decreased MTHFR activity appear at risk of higher MTX toxicity. Because of the high prevalence of the TT genotype, these results may have implications for MTX dosage...
  83. ncbi request reprint Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning
    M E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Department of Medicine, University of Washington, Seattle, WA, USA
    Bone Marrow Transplant 35:277-82. 2005
    ..Assessment of serious GVHD provides additional useful information to acute GVHD grades and classification of limited and extensive chronic GVHD in describing the overall risk and impact complications caused by donor cells...
  84. ncbi request reprint Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease
    L Giaccone
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Bone Marrow Transplant 36:337-41. 2005
    ..From this preliminary analysis, MTX appears to be a well-tolerated, inexpensive and possibly steroid-sparing agent that is worthy of further evaluation in prospective trials for treatment of chronic GVHD...
  85. ncbi request reprint Cellular, serological, and molecular polymorphism of the class I and class II loci of the canine Major Histocompatibility Complex
    J L Wagner
    Transplantation Biology Program, Fred Hutchinson Cancer Research Center, Seatle, WA, USA
    Tissue Antigens 59:205-10. 2002
    ....
  86. ncbi request reprint Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 97:3380-9. 2001
    ..008). In conclusion, blood stem cell recipients have higher lymphocyte-subset counts and this appears to result in fewer infections. (Blood. 2001;97:3380-3389)..
  87. ncbi request reprint Secondary failure of platelet recovery after hematopoietic stem cell transplantation
    B Bruno
    The Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington Medical School, Seattle 98109-1024, USA
    Biol Blood Marrow Transplant 7:154-62. 2001
    ..The identification of the characteristics and risk factors for SFPR could improve patient counseling and management and lead to the design of effective treatment strategies...
  88. ncbi request reprint An improved method for dog leukocyte antigen 88 typing and two new major histocompatibility complex class I alleles, DLA-88*01101 and DLA-88*01201
    G M Venkataraman
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, D1 100 Seattle, WA 98109, USA
    Tissue Antigens 70:53-7. 2007
    ..The method is reliable in typing dogs for the class I dog leukocyte antigen (DLA)-88 locus, and through its use, we describe here two new alleles DLA-88*01101 and DLA-88*01201...
  89. ncbi request reprint L-histidinol provides effective selection of retrovirus-vector-transduced keratinocytes without impairing their proliferative potential
    M A Stockschlaeder
    Fred Hutchinson Cancer Research Center, Seattle, WA 98104
    Hum Gene Ther 2:33-9. 1991
    ..Our results suggest that hisD will be a useful selectable marker for use in studies of keratinocyte differentiation and for transfer of genes into keratinocytes for the purposes of gene therapy...
  90. ncbi request reprint Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes
    G E Georges
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle 98109, USA
    Blood 98:3447-55. 2001
    ..These results show that ex vivo expanded, transduced T cells maintained in vivo function and enhanced marrow engraftment...
  91. pmc Therapy with mycophenolate mofetil for refractory acute and chronic GVHD
    T Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Bone Marrow Transplant 44:739-48. 2009
    ..The area under the curve plasma concentrations of mycophenolic acid seemed to be suboptimal among patients with acute GVHD but not among those with chronic GVHD. MMF can be used effectively for treatment of GVHD...
  92. ncbi request reprint Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients
    G Mathioudakis
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 96:3991-4. 2000
    ..These data suggest that under standard transplantation conditions, the stem cell proliferative potential is not compromised during hematopoietic reconstitution. (Blood. 2000;96:3991-3994)..
  93. ncbi request reprint Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
    W I Bensinger
    Clinical Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 344:175-81. 2001
    ..However, the relative effects of these techniques on the rates of acute and chronic graft-versus-host disease, overall survival, and disease-free survival have not been determined in randomized studies...
  94. ncbi request reprint Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation
    J Storek
    Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA
    Blood 98:3505-12. 2001
    ..Patients who received transplants in adulthood have a clinically insignificant deficiency of de novo-generated CD4 T cells, suggesting that in these patients the posttransplantation thymic insufficiency may not be fully reversible...
  95. ncbi request reprint Graft-versus-host effect after allogeneic hematopoietic stem cell transplantation: GVHD and GVL
    R A Nash
    Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA
    Curr Opin Immunol 8:674-80. 1996
    ....
  96. pmc Prevention of graft-vs.-host disease
    Andrew R Rezvani
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, Seattle, WA 98109, USA
    Expert Opin Pharmacother 13:1737-50. 2012
    ..However, graft-vs.-host disease (GVHD) remains a major complication of allogeneic HCT and limits the success of this approach...
  97. pmc Ultrasound-targeted microbubble destruction-mediated gene delivery into canine livers
    Misty L Noble
    Center for Immunity and Immunotherapies, Seattle Children s Research Institute, Seattle, Washington 98101, USA
    Mol Ther 21:1687-94. 2013
    ..7 MPa. Transaminase and histology analysis indicated minimal tissue damage. These experiments represent an important developmental step toward US-mediated gene delivery in large animals and clinics...
  98. pmc HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
    Leo Luznik
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 14:641-50. 2008
    ..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD...
  99. ncbi request reprint Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia
    Robert Iannone
    Department of Pediatrics, Johns Hopkins Hospital and Oncology Center, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 9:519-28. 2003
    ....
  100. pmc Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders
    Ginna G Laport
    Stanford University Medical Center, Stanford, California 94305 5623, USA
    Biol Blood Marrow Transplant 14:246-55. 2008
    ..Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure...
  101. ncbi request reprint Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce dura
    Dietger Niederwieser
    Division of Hematology and Oncology, University of Leipzig, Germany
    Blood 101:1620-9. 2003
    ..HCT from HLA-matched or mismatched unrelated donors can be performed with a reduced intensity conditioning regimen in patients ineligible for conventional HCT...

Research Grants13

  1. HEMATOPOIETIC GROWTH FACTORS IN A CANINE STEM CELL MODEL
    Rainer Storb; Fiscal Year: 2001
    ....
  2. HEMATOPOIETIC GROWTH FACTORS IN A CANINE STEM CELL MODEL
    Rainer Storb; Fiscal Year: 2000
    ....
  3. HEMATOPOIETIC GROWTH FACTOR IN GRAFT MODEL
    Rainer Storb; Fiscal Year: 1993
    ..Along with the planned in vivo studies, we propose to clone the genes encoding for canine hematopoietic growth factors and produce the equivalent proteins which will allow us to substitute canine for human recombinant growth factors...
  4. HEMATOPOIETIC GROWTH FACTOR IN GRAFT MODEL
    Rainer Storb; Fiscal Year: 1992
    ..Along with the planned in vivo studies, we propose to clone the genes encoding for canine hematopoietic growth factors and produce the equivalent proteins which will allow us to substitute canine for human recombinant growth factors...
  5. HEMATOPOIETIC GROWTH FACTOR IN GRAFT MODEL
    Rainer Storb; Fiscal Year: 1991
    ..Along with the planned in vivo studies, we propose to clone the genes encoding for canine hematopoietic growth factors and produce the equivalent proteins which will allow us to substitute canine for human recombinant growth factors...
  6. HEMATOPOIETIC GROWTH FACTOR IN GRAFT MODEL
    Rainer Storb; Fiscal Year: 1990
    ..Along with the planned in vivo studies, we propose to clone the genes encoding for canine hematopoietic growth factors and produce the equivalent proteins which will allow us to substitute canine for human recombinant growth factors...
  7. HEMATOPOIETIC GROWTH FACTORS IN A CANINE STEM CELL MODEL
    Rainer Storb; Fiscal Year: 1999
    ....